- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00828503
Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients (Certi-CMV)
A prospective, randomized safety and efficacy study of Certican® as add-on therapy against CMV disease in renal transplant recipients
OBJECTIVES:
Primary Objective:
To demonstrate efficacy of Certican® as add-on therapy against CMV disease in comparison to either valcyte® (valganciclovir) or cymevene® (ganciclovir) alone, evaluated by quantitative measurement of CMV-DNA with PCR from the blood (qCMV-PCR)
Secondary Objectives:
To assess safety and tolerability of Certican® in patients with CMV- disease To study the effects of Certican® treatment on quality of life
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
DESIGN / PHASE Prospective, single-center, randomized, parallel group, controlled, phase II study.
PATIENTS / GROUPS 40 patients in 2 groups 20 patients per group Randomization ratio 1:1, no stratification
INVESTIGATIONAL DRUG Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgment of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)
COMPARATIVE DRUG No therapy (add-on design
CONCOMITANT MEDICATION Allowed The concomitant immunosuppressive medication will be adjusted to the additional administration of Certican®. For example, if the patient already receives cyclosporine A or tacrolimus, this will be adjusted, according to the current recommendations4 at the judgment of the clinical investigator
TOLERABILITY / SAFETY ENDPOINTS:
Rejection Hematocrit Platelet count WBC count Wound healing disorders Blood lipids (cholesterol, triglycerides) Infections (other than CMV)
PHARMACOKINETIC / PHARMACODYNAMIC ENDPOINTS Certican® (everolimus) trough levels
STATISTICAL METHODOLOGY Primary Endpoint: CMV-load (copies/mL)
Null and alternative hypotheses:
H0 Treatment with Certican® (everolimus) in combination with valcyte® (valganciclovir) or cymevene® (ganciclovir) is equal to valcyte® (valganciclovir) or cymevene® (ganciclovir) alone in reducing the CMV-load in renal transplant patients with CMV-disease H1: Treatment with Certican® (everolimus) in combination with valcyte® (valganciclovir) or cymevene® (ganciclovir) is superior to valcyte® (valganciclovir) or cymevene® (ganciclovir) in reducing CMV load (copies/mL) in renal transplant patients with CMV-disease Type-I and -II errors - power. α=0.05 ß=0.2 (power 0.8) Statistical methodology ANOVA of repeated measures (CMV-copies/mL), one-sided t-test of CMV load at distinct time-points, one-sided t-test of the time (in weeks) until CMV-load reaches ≤600 copies/mL Sample size calculation Based on a one-sided testing and a σ of 0.2 in relative changes of CMV-copies, an α=0.05 And a ß=0.2 a sample size of 20 patients per group was determined. Main analysis set Per-protocol (efficacy) and intention to treat (ITT) for safety Other endpoints Bonferroni corrected t-tests will be performed for CMV-copies/mL at each time point of the follow-up period. The time to copies ≤ 600 will also be analyzed by a t-test. All other secondary endpoints and subgroup analysis will be performed in explorative intention (descriptive statistics).
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Marcus D Säemann, MD
- Phone Number: +431404005593
- Email: marcus.saemann@meduniwien.ac.at
Study Contact Backup
- Name: Manfred Hecking, MD
- Phone Number: +431404005593
- Email: manfred.hecking@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Medical University of Vienna
-
Sub-Investigator:
- Manfred Hecking, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
CMV-disease after renal transplantation, i.e.,(1.) CMV present in the blood, and (2.) one of the following symptoms (for viral syndrome, from the American Society of Transplantation recommendations for use in clinical trials1):
- body temperature ≥ 38°C
- new or increased significant malaise
- leucopenia (< 3500/mL)
- atypical lymphocytosis ≥ 5%
- thrombocytopenia (platelets < 100.000/mL)
- no other cause of symptoms/signs identified
- informed consent of the patient
Exclusion Criteria:
- patients with a known hypersensitivity to everolimus, sirolimus or any of the excipients
- administration of strong CYP3A4 Inhibitors (e.g. ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin) and inducers (rifampicin), unless the benefit outweighs the risk, according to the judgment of the clinical investigator
- acute rejection episodes in the first 3 months after renal transplantation
- active hepatitis in the previous month
- Significant proteinuria (> 0.8g/24h Urine)
- hepatic impairment, according to the criteria defined by Bénichou et al.2: a singular elevation of GPT or conjugated bilirubin to a value twice above the normal level, or a combined elevation of GOT, AP, and total bilirubin, given that at least one parameter is twice above the normal level
- hematocrit < 25%
- any significant wound healing disorder (anamnestic)
- blood white blood cell (WBC) count < 3000/mL
- platelets < 50.000/mL
- severe dyslipidemia (cholesterol >300mg/dL, triglycerides > 350mg/dL)
- uncontrolled hypertension (continuous episodes of hypertension above 140/90 (WHO classification and American Society of Transplantation recommendations 3) despite adequate hypertensive therapy)
- uncontrolled hyperuricemia (uric acid > 8mg/dL)
- pregnancy
- any immunosuppressive protocol which does not allow the addition of Certican®, according to the judgment of the clinical investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 1 Certican + Valganciclovir
Valganciclovir will be administered and Certican (everolimus) will be added as immunosuppression
|
Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments) MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily) |
ACTIVE_COMPARATOR: 2 Valganciclovir alone
Valganciclovir will be added alone.
|
Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v.
twice daily)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
relative changes in CMV-load (copies/mL), as determined by qCMV-PCR from whole blood throughout the observational period
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CMV-load (copies/mL) after 1-8 weeks, in months 3, 4, 6 and 12; Time (in weeks) until the CMV-load reaches ≤600 copies/mL
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Sabine Schmaldienst, MD, Medical University of Vienna
Publications and helpful links
General Publications
- Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006 Feb;6(2):262-74. doi: 10.1111/j.1600-6143.2005.01207.x.
- Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990 Sep;11(2):272-6. doi: 10.1016/0168-8278(90)90124-a.
- Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. 2000 Oct;11 Suppl 15:S1-86.
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EudraCT: 2008-004745-28
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytomegalovirus Disease
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus Infection | Cytomegalovirus DiseaseJapan
-
University of Sao Paulo General HospitalCompletedCytomegalovirus DiseaseBrazil
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedCytomegalovirus Infection | Viral DiseaseFrance
-
Foundation IRCCS San Matteo HospitalFondazione Regionale per la Ricerca Biomedica (FRRB) - Regione LombardiaUnknownCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionItaly
-
Rabin Medical CenterCompletedCongenital Cytomegalovirus InfectionIsrael
-
National Institute of Allergy and Infectious Diseases...Completed
-
BiotestActive, not recruitingCongenital Cytomegalovirus InfectionGermany
-
Central Hospital, Nancy, FranceCompletedCongenital Cytomegalovirus InfectionFrance
-
NobelpharmaCompletedCytomegalovirus DiseaseUnited States, Japan
Clinical Trials on Certican (everolimus) + valganciclovir
-
Ahmad TarhiniNovartis PharmaceuticalsCompletedSmall Cell Lung CancerUnited States
-
Novartis PharmaceuticalsCompleted
-
National Health Research Institutes, TaiwanNovartisUnknownHepatocellular CarcinomaTaiwan
-
University of BolognaUnknownHeart Transplantation | Cytomegalovirus Infection | Cardiac Allograft VasculopathyItaly
-
Hospital Universitário São JoséUnknownDisorder Related to Renal TransplantationBrazil
-
University of UtahNovartisTerminatedPeutz-Jeghers SyndromeUnited States
-
Novartis PharmaceuticalsWithdrawnKidney TransplantationSwitzerland
-
Rabin Medical CenterCompletedChronic Rejection of Cardiac TransplantIsrael
-
Novartis PharmaceuticalsCompletedKidney TransplantationUnited States, Belgium
-
Novartis PharmaceuticalsCompletedHeart TransplantationSpain, United States, Austria, Italy, Canada, Germany, Australia, Brazil